These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37410085)

  • 21. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
    Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.
    Einarsson JT; Evert M; Geborek P; Saxne T; Lundgren M; Kapetanovic MC
    Clin Rheumatol; 2017 Dec; 36(12):2743-2750. PubMed ID: 28980088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe infections in patients with ANCA-associated vasculitis treated with rituximab.
    Segelmark L; Flores-Suárez L; Mohammad A
    Rheumatology (Oxford); 2021 Dec; 61(1):205-212. PubMed ID: 33757116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should complete B cell depletion be maintained in patients treated long-term with rituximab for rheumatoid arthritis?
    Ghossan R; Al Tabaa O; Combier A; Steelandt A; Thomas M; Fogel O; Miceli-Richard C; Molto A; Allanore Y; Avouac J
    Rheumatology (Oxford); 2024 Aug; 63(8):2135-2141. PubMed ID: 37792482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
    Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
    BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comprehensive review of rituximab therapy in rheumatoid arthritis patients.
    Tavakolpour S; Alesaeidi S; Darvishi M; GhasemiAdl M; Darabi-Monadi S; Akhlaghdoust M; Elikaei Behjati S; Jafarieh A
    Clin Rheumatol; 2019 Nov; 38(11):2977-2994. PubMed ID: 31367943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eficiency of different doses of rituximab in rheumatoid arthritis.
    Mena-Vázquez N; Manrique-Arija S; Ureña-Garnica I; Romero-Barco CM; Jiménez-Núñez FG; Coret V; Irigoyen-Oyarzábal MV; Fernández-Nebro A
    Reumatol Clin; 2016; 12(3):139-45. PubMed ID: 26458761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Silva-Fernández L; De Cock D; Lunt M; Low AS; Watson KD; ; Symmons DPM; Hyrich KL
    Rheumatology (Oxford); 2018 Sep; 57(9):1533-1540. PubMed ID: 28968862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study.
    Lazarou I; Finckh A; Fischer L; Ribi C; Gascon D; Seebach JD; Guerne PA
    Joint Bone Spine; 2016 Mar; 83(2):191-7. PubMed ID: 26677998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
    Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
    Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
    Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis.
    van der Togt CJT; Ten Cate DF; van den Bemt BJF; Rahamat-Langendoen J; den Broeder N; den Broeder AA
    Rheumatology (Oxford); 2023 Apr; 62(4):1627-1630. PubMed ID: 36000861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.
    Combier A; Nocturne G; Henry J; Belkhir R; Pavy S; Le Tiec C; Descamps E; Seror R; Mariette X
    Rheumatology (Oxford); 2020 Jun; 59(6):1347-1354. PubMed ID: 31613955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
    Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
    Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
    MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
    Gottenberg JE; Ravaud P; Bardin T; Cacoub P; Cantagrel A; Combe B; Dougados M; Flipo RM; Godeau B; Guillevin L; Le Loët X; Hachulla E; Schaeverbeke T; Sibilia J; Baron G; Mariette X;
    Arthritis Rheum; 2010 Sep; 62(9):2625-32. PubMed ID: 20506353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
    Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
    Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg
    Kuo MH; Tseng CW; Lee CH; Tung CH; Tseng KC; Lai NS
    Sci Rep; 2020 Feb; 10(1):2456. PubMed ID: 32051458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis.
    Giraud C; Tatar Z; Soubrier M
    Clin Rheumatol; 2016 Oct; 35(10):2615-8. PubMed ID: 27541023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
    Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.